Aminex Therapeutics is a clinical stage, immuno-oncology company pioneering the development of improved treatments for solid tumors based on blocking the polyamine pathway essential to tumor growth and evasion of the immune response. Polyamines have been well-established over more than 40 years as being elevated in many cancers and essential for rapid cell growth and division. Recent discoveries, many pioneered by Aminex Therapeutics, show that polyamines also regulate the tumor micro-environment’s immune response to cancer. Aminex’s novel cancer immunotherapy drug, AMXT 1501/DFMO, engages, in multiple animal trials, the immune system to attack and clear cancer primary tumors and its metastases. AMXT 1501/DFMO negates two major immune system suppressors–polyamines and myeloid-derived suppressor cells (MDSCs). Further, it compromises the cancer-driving roles of both the MYC and RAS oncogenes, thought to be involved with more than sixty percent of solid tumors.